HomeCompareKIN vs MO

KIN vs MO: Dividend Comparison 2026

KIN yields 21.62% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KIN wins by $2.9K in total portfolio value
10 years
KIN
KIN
● Live price
21.62%
Share price
$9.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.6K
Annual income
$7,983.46
Full KIN calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — KIN vs MO

📍 KIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKINMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KIN + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KIN pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KIN
Annual income on $10K today (after 15% tax)
$1,837.84/yr
After 10yr DRIP, annual income (after tax)
$6,785.94/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $17,837.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KIN + MO for your $10,000?

KIN: 50%MO: 50%
100% MO50/50100% KIN
Portfolio after 10yr
$79.2K
Annual income
$18,476.00/yr
Blended yield
23.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

KIN
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KIN buys
0
MO buys
0
No recent congressional trades found for KIN or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKINMO
Forward yield21.62%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$80.6K$77.7K
Annual income after 10y$7,983.46$28,968.54
Total dividends collected$47.7K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: KIN vs MO ($10,000, DRIP)

YearKIN PortfolioKIN Income/yrMO PortfolioMO Income/yrGap
1← crossover$12,862$2,162.16$10,558$768.31+$2.3KKIN
2$16,362$2,599.07$11,352$1,015.87+$5.0KKIN
3$20,597$3,089.91$12,482$1,367.86+$8.1KKIN
4$25,674$3,635.27$14,103$1,883.39+$11.6KKIN
5$31,706$4,234.91$16,472$2,664.91+$15.2KKIN
6$38,813$4,887.76$20,024$3,897.79+$18.8KKIN
7$47,122$5,591.96$25,537$5,933.74+$21.6KKIN
8$56,765$6,344.91$34,478$9,476.77+$22.3KKIN
9$67,882$7,143.35$49,776$16,022.63+$18.1KKIN
10$80,618$7,983.46$77,699$28,968.54+$2.9KKIN

KIN vs MO: Complete Analysis 2026

KINStock

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

Full KIN Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this KIN vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KIN vs SCHDKIN vs JEPIKIN vs OKIN vs KOKIN vs MAINKIN vs PMKIN vs BTIKIN vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.